4d Molecular Therapeutics vs Verastem
4d Molecular Therapeutics is the larger business, with $85.2m of revenue in fiscal 2025 against $30.9m for Verastem (2.8 times as much). 4d Molecular Therapeutics grew faster (230194.6% against 209.1%). 4d Molecular Therapeutics kept more of each dollar of sales as profit: a net margin of -164.4% against -677.6%. 4d Molecular Therapeutics carries less debt relative to equity (0.0% against 133.5%).
| Latest fiscal year | 4d Molecular TherapeuticsFDMT, 2025 | VerastemVSTM, 2025 |
|---|---|---|
| Revenue | $85.2m | $30.9m |
| Revenue growth | 230194.6% | 209.1% |
| Net income | −$140m | −$209m |
| Operating margin | -187.2% | -550.3% |
| Net margin | -164.4% | -677.6% |
| Return on equity | -27.6% | — |
| Free cash flow | −$110m | −$138m |
| Cash | $60.2m | $205m |
| Total debt | $0 | $76.3m |
| Debt to equity | 0.0% | 133.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 196 | 102 |
| Market value | $656m | $884m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 28 (Weak) |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 33 sales |